{
    "ticker": "KIO",
    "name": "Kiora Pharmaceuticals, Inc.",
    "description": "Kiora Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. Founded in 2015, Kiora is dedicated to addressing unmet medical needs in the eye care sector through the development of novel drug candidates and formulations. The company\u2019s lead product, KIO-301, is designed for the treatment of dry eye disease, a common condition that affects millions of people worldwide. Kiora utilizes its proprietary drug delivery technologies to enhance the efficacy and safety of its therapies. The company's mission is to improve the quality of life for patients suffering from debilitating eye conditions by providing effective and safe treatment options. In addition to KIO-301, Kiora is engaged in the research and development of other pipeline candidates aimed at treating various ocular disorders. With a team of experienced professionals in the pharmaceutical and biotech industries, Kiora is committed to advancing its product candidates through clinical trials and ultimately bringing them to market. The company is headquartered in New York, NY, and is focused on strategic partnerships and collaborations to enhance its research capabilities and accelerate development timelines.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2015",
    "website": "https://www.kiorapharma.com",
    "ceo": "David S. K. Kahn",
    "social_media": {
        "twitter": "https://twitter.com/KioraPharma",
        "linkedin": "https://www.linkedin.com/company/kiora-pharmaceuticals"
    },
    "investor_relations": "https://ir.kiorapharma.com",
    "key_executives": [
        {
            "name": "David S. K. Kahn",
            "position": "CEO"
        },
        {
            "name": "Michael L. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapies",
            "products": [
                "KIO-301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kiora Pharmaceuticals, Inc. | Innovative Ophthalmic Therapies",
        "meta_description": "Explore Kiora Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for ophthalmic diseases. Learn about Kiora's commitment to improving patient outcomes.",
        "keywords": [
            "Kiora Pharmaceuticals",
            "Ophthalmic Diseases",
            "Biotechnology",
            "Pharmaceuticals",
            "KIO-301"
        ]
    },
    "faq": [
        {
            "question": "What is Kiora Pharmaceuticals known for?",
            "answer": "Kiora Pharmaceuticals is known for developing innovative therapies for ophthalmic diseases, particularly its lead product KIO-301 for dry eye disease."
        },
        {
            "question": "Who is the CEO of Kiora Pharmaceuticals?",
            "answer": "David S. K. Kahn is the CEO of Kiora Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Kiora Pharmaceuticals headquartered?",
            "answer": "Kiora Pharmaceuticals is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Kiora's main products?",
            "answer": "Kiora's main products include KIO-301, which is aimed at treating dry eye disease."
        },
        {
            "question": "When was Kiora Pharmaceuticals founded?",
            "answer": "Kiora Pharmaceuticals was founded in 2015."
        }
    ],
    "competitors": [
        "REGN",
        "RDN",
        "AERI"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BIIB"
    ]
}